Found this stock using a MarketBeat Screening Report that show stocks with a large # of Buy to Strong Buy ratings with recent low prices/dips but with at least an analyst target price of 3X the current price. I then saw the Hedge + Insider purchases were immense recently and they have an upcoming catalyst of potential drug approval in June 2025. My plan was to hold until then but a 95%+ gain is hard to say no to. I cashed in half my shares, covered my initial investment and I’ll let the other half ride until late June 2025. Currently bought in big to $GRAB, $VRT, $LUNR, $ACHR, and $OKLO. If you’re looking for a similar BioPharma stock I’d recommend $UNCY. Do your DD but they have the same catalyst coming up in late June and are only $0.63/share.